Freedom of Information request on the side effects reported for Benzydamine Hydrochloride (Difflam) (FOI 21/1240)
Published 31 May 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-13-december-2021/freedom-of-information-request-on-the-side-effects-reported-for-benzydamine-hydrochloride-difflam-foi-211240
FOI 21/1240
13th December 2021
Dear,
Thank you for your FOI request dated 21st November 2021, where you requested information regarding the side effects reported for Benzydamine Hydrochloride (Difflam).
The MHRA collects data concerning any adverse reactions observed to medicines and medical devices through our Yellow Card scheme. Yellow Card data for drugs is routinely published on the Yellow Card website https://yellowcard.mhra.gov.uk/iDAP/ and the information you have requested can be found at the link below:
If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely,
FOI Team,
Vigilance and Risk Management of Medicines Division